Last reviewed · How we verify
VLI
VLI is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, disrupting cell division and causing cell death in rapidly dividing cancer cells.
VLI is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, disrupting cell division and causing cell death in rapidly dividing cancer cells. Used for Hodgkin lymphoma, Non-Hodgkin lymphoma, Acute lymphoblastic leukemia.
At a glance
| Generic name | VLI |
|---|---|
| Sponsor | Spectrum Pharmaceuticals, Inc |
| Drug class | Vinca alkaloid |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Vinca alkaloids like VLI bind to β-tubulin and prevent microtubule polymerization, which disrupts the mitotic spindle formation necessary for cell division. This leads to metaphase arrest and apoptosis in cancer cells. The drug is particularly effective against rapidly dividing cells with high mitotic activity.
Approved indications
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Acute lymphoblastic leukemia
- Breast cancer
- Lung cancer
- Testicular cancer
Common side effects
- Neutropenia
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Constipation
- Alopecia
Key clinical trials
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (PHASE2)
- Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy (PHASE1, PHASE2)
- Incretin Effects of Branched Chain Amino Acids (NA)
- Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VLI CI brief — competitive landscape report
- VLI updates RSS · CI watch RSS
- Spectrum Pharmaceuticals, Inc portfolio CI